Abstract
A comparison was made of the plasma concentrations of ranitidine base in 12 normal volunteers after the administration of 100 mg intravenously and in 6 patients with terminal renal failure after 40 mg intravenously off and then during haemodialysis. The plasma ranitidine concentrations were determined by radioimmunoassay. The results suggest that reduced elimination of the drug occurs in patients with severe renal failure and that there is significant removal of the drug during haemodialysis. It is suggested that dosage reduction is advisable in patients with severe renal failure and a suitable schedule for such patients is described.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Carey P. F., Martin L. E., Owen P. E. Determination of ranitidine and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography. J Chromatogr. 1981 Sep 11;225(1):161–168. doi: 10.1016/s0378-4347(00)80255-8. [DOI] [PubMed] [Google Scholar]
- Jenner W. N., Martin L. E., Willoughby B. A., Fellows I. The development of a radioimmunoassay for ranitidine in biological fluids. Life Sci. 1981 Mar 23;28(12):1323–1329. doi: 10.1016/0024-3205(81)90404-5. [DOI] [PubMed] [Google Scholar]
- Peden N. R., Richards D. A., Saunders J. H., Wormsley K. G. Pharmacologically effective plasma concentrations of ranitidine. Lancet. 1979 Jul 28;2(8135):199–200. doi: 10.1016/s0140-6736(79)91466-1. [DOI] [PubMed] [Google Scholar]
- Peden N. R., Saunders J. H., Wormsley K. G. Inhibition of pentagastrin-stimulated and nocturnal gastric secretion by ranitidine. A new H2-receptor antagonist. Lancet. 1979 Mar 31;1(8118):690–692. doi: 10.1016/s0140-6736(79)91146-2. [DOI] [PubMed] [Google Scholar]